The O
Type O
II O
C2 O
null O
allele O
( O
C2Q0 O
) O
is O
linked O
to O
two O
major O
histocompatibility O
haplotypes O
( O
MHC O
) O
that O
differ O
from O
the O
MHC O
of O
the O
more O
common O
Type B
I I
C2 I
deficiency I
. O

Subsequent O
molecular O
biology O
, O
biosynthetic O
, O
and O
immunofluorescence O
studies O
demonstrated O
that O
C2 O
secretion O
is O
impaired O
in O
Type B
II I
C2 I
deficiency I
because O
of O
different O
missense O
mutations O
at O
highly O
conserved O
residues O
in O
each O
of O
the O
C2Q0 O
alleles O
. O

Wiskott B
- I
Aldrich I
syndrome I
protein O
, O
a O
novel O
effector O
for O
the O
GTPase O
CDC42Hs O
, O
is O
implicated O
in O
actin O
polymerization O
. O

We O
have O
identified O
WASP O
, O
the O
protein O
that O
is O
defective O
in O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
, O
as O
a O
novel O
effector O
for O
CDC42Hs O
, O
but O
not O
for O
the O
other O
Rho O
family O
members O
, O
Rac O
and O
Rho O
. O

X B
- I
linked I
adrenoleukodystrophy I
is O
a O
frequent O
cause O
of O
idiopathic O
Addison B
' I
s I
disease I
in O
young O
adult O
male O
patients O
. O

X B
- I
linked I
adrenoleukodystrophy I
is O
a O
frequent O
cause O
of O
idiopathic O
Addison B
' I
s I
disease I
in O
young O
adult O
male O
patients O
. O

X B
- I
Linked I
adrenoleukodystrophy I
( O
ALD B
) O
is O
a O
genetic B
disease I
associated O
with O
demyelination B
of I
the I
central I
nervous I
system I
, O
adrenal B
insufficiency I
, O
and O
accumulation O
of O
very O
long O
chain O
fatty O
acids O
in O
tissue O
and O
body O
fluids O
. O

Nine O
different O
germ O
- O
line O
mutations O
in O
the O
BRCA1 O
breast B
and I
ovarian I
cancer I
susceptibility O
gene O
were O
identified O
in O
15 O
of O
47 O
kindreds O
from O
southern O
Sweden O
, O
by O
use O
of O
SSCP O
and O
heteroduplex O
analysis O
of O
all O
exons O
and O
flanking O
intron O
region O
and O
by O
a O
protein O
- O
truncation O
test O
for O
exon O
11 O
, O
followed O
by O
direct O
sequencing O
. O

Eleven O
of O
the O
15 O
kindreds O
manifesting O
BRCA1 O
mutations O
were O
breast B
- I
ovarian I
cancer I
families O
, O
several O
of O
them O
with O
a O
predominant O
ovarian B
cancer I
phenotype O
. O

The O
set O
of O
32 O
families O
in O
which O
no O
BRCA1 O
alterations O
were O
detected O
included O
1 O
breast B
- I
ovarian I
cancer I
kindred O
manifesting O
clear O
linkage O
to O
the O
BRCA1 O
region O
and O
loss O
of O
the O
wild O
- O
type O
chromosome O
in O
associated O
tumors B
. O

We O
have O
developed O
a O
multiplex O
heteroduplex O
analysis O
that O
is O
designed O
to O
analyze O
one O
- O
quarter O
of O
the O
coding O
sequence O
in O
a O
single O
- O
step O
screening O
procedure O
and O
that O
will O
detect O
approximately O
50 O
% O
of O
all O
BRCA1 O
mutations O
so O
far O
reported O
in O
breast B
/ I
ovarian I
cancer I
families O
. O

A O
previously O
undescribed O
mutation O
within O
the O
tetramerisation O
domain O
of O
TP53 O
in O
a O
family O
with O
Li B
- I
Fraumeni I
syndrome I
. O

We O
report O
details O
of O
a O
family O
with O
classic O
Li B
- I
Fraumeni I
syndrome I
in O
which O
there O
is O
a O
mutation O
in O
codon O
344 O
of O
the O
tumour B
suppressor O
gene O
TP53 O
. O

The O
mouse O
homolog O
of O
the O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
WASP O
) O
gene O
is O
highly O
conserved O
and O
maps O
near O
the O
scurfy O
( O
sf O
) O
mutation O
on O
the O
X O
chromosome O
. O

The O
mouse O
WASP O
gene O
, O
the O
homolog O
of O
the O
gene O
mutated O
in O
Wiskott B
- I
Aldrich I
syndrome I
, O
has O
been O
isolated O
and O
sequenced O
. O
the O
predicted O
amino O
acid O
sequence O
is O
86 O
% O
identical O
to O
the O
human O
WASP O
sequence O
. O

This O
localization O
makes O
Wasp O
a O
candidate O
for O
involvement O
in O
scurfy O
, O
a O
T O
cell O
- O
mediated O
fatal B
lymphoreticular I
disease I
of O
mice O
that O
has O
previously O
been O
proposed O
as O
a O
mouse O
homolog O
of O
Wiskott B
- I
Aldrich I
syndrome I
. O

Mutations O
of O
the O
BRCA1 O
gone O
in O
humans O
are O
associated O
with O
predisposition O
to O
breast B
and I
ovarian I
cancers I
. O

Wiskott B
- I
Aldrich I
syndrome I
: O
no O
strict O
genotype O
- O
phenotype O
correlations O
but O
clustering O
of O
missense O
mutations O
in O
the O
amino O
- O
terminal O
part O
of O
the O
WASP O
gene O
product O
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
WASP O
) O
gene O
was O
found O
to O
be O
mutated O
in O
patients O
presenting O
with O
WAS B
and O
in O
patients O
showing O
X B
- I
linked I
thrombocytopenia I
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
WASP O
) O
gene O
was O
found O
to O
be O
mutated O
in O
patients O
presenting O
with O
WAS B
and O
in O
patients O
showing O
X B
- I
linked I
thrombocytopenia I
. O

Our O
results O
show O
that O
huntingtin O
is O
cleaved O
by O
cysteine O
proteases O
and O
suggest O
that O
HD B
might O
be O
a O
disorder B
of I
inappropriate I
apoptosis I
. O
. O

To O
begin O
to O
address O
the O
hypothesis O
that O
abnormal O
regulation O
of O
the O
breast B
/ I
ovarian I
cancer I
susceptibility O
gene O
BRCA1 O
is O
a O
critical O
step O
in O
sporadic O
breast O
/ O
ovarian O
tumorigenesis O
, O
we O
have O
determined O
the O
detailed O
structure O
of O
the O
BRCA1 O
genomic O
region O
. O

Deletion O
of O
small O
nuclear O
ribonucleoprotein O
polypeptide O
N O
( O
SNRPN O
) O
in O
Prader B
- I
Willi I
syndrome I
detected O
by O
fluorescence O
in O
situ O
hybridization O
: O
two O
sibs O
with O
the O
typical O
phenotype O
without O
a O
cytogenetic O
deletion O
in O
chromosome O
15q O
. O

The O
small O
nuclear O
ribonucleoprotein O
polypeptide O
N O
( O
SNRPN O
) O
gene O
is O
regarded O
as O
one O
of O
the O
candidates O
for O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

In O
addition O
, O
somatic O
Inactivation O
of O
the O
VHL B
gene O
is O
frequent O
in O
sporadic B
renal I
cell I
carcinoma I
and O
haemangioblastoma B
. O

Genetic O
analysis O
was O
undertaken O
to O
establish O
linkage O
between O
the O
breast B
or I
ovarian I
cancer I
cases O
and O
markers O
on O
chromosomes O
17q O
( O
BRCA1 O
) O
and O
13q O
( O
BRCA2 O
) O
. O

An O
intronic O
mutation O
in O
a O
lariat O
branchpoint O
sequence O
is O
a O
direct O
cause O
of O
an O
inherited B
human I
disorder I
( O
fish B
- I
eye I
disease I
) O
. O

Three O
sisters O
were O
shown O
to O
suffer O
from O
fish B
- I
eye I
disease I
( O
FED B
) O
, O
a O
disorder O
which O
is O
caused O
by O
mutations O
in O
the O
gene O
coding O
for O
lecithin O
cholesterol O
acyltransferase O
( O
LCAT O
) O
. O

To O
define O
the O
possible O
role O
of O
the O
VHL B
gene O
in O
the O
development O
of O
sporadic B
renal I
cell I
carcinomas I
, O
91 O
different O
parenchymal B
tumours I
of I
the I
kidney I
have O
been O
investigated O
for O
mutation O
of O
the O
VHL B
gene O
by O
single O
strand O
conformation O
polymorphism O
( O
SSCP O
) O
and O
/ O
or O
heteroduplex O
( O
HD O
) O
techniques O
. O

In O
addition O
, O
15 O
papillary B
renal I
cell I
tumours I
and O
ten O
renal B
oncocytomas I
, O
which O
are O
characterized O
by O
genetic O
changes O
other O
than O
loss O
of O
chromosome O
3p O
sequences O
, O
were O
analysed O
for O
mutation O
of O
the O
VHL B
gene O
. O

Although O
this O
microsatellite B
instability I
has O
been O
attributed O
to O
mutations O
in O
four O
DNA O
mismatch O
repair O
genes O
in O
hereditary B
nonpolyposis I
colorectal I
cancer I
( O
HNPCC B
) O
kindreds O
, O
many O
sporadic B
tumours I
exhibit O
instability O
but O
no O
detectable O
mutations O
in O
these O
genes O
. O

However O
, O
in O
a O
small O
subset O
of O
hemizygous O
males O
who O
suffer O
from O
chronic B
nonspherocytic I
hemolytic I
anemia I
, O
the O
underlying O
mutations O
( O
designated O
class O
I O
) O
cause O
more O
- O
severe O
G6PD B
deficiency I
, O
and O
this O
might O
provide O
an O
opportunity O
for O
selection O
in O
heterozygous O
females O
during O
development O
. O

The O
human O
neuronal O
nicotinic O
acetylcholine O
receptor O
alpha O
4 O
subunit O
gene O
( O
CHRNA4 O
) O
is O
located O
in O
the O
candidate O
region O
for O
three O
different O
phenotypes O
benign B
familial I
neonatal I
convulsions I
, O
autosomal B
dominant I
nocturnal I
frontal I
lobe I
epilepsy I
, O
and O
low O
- O
voltage O
EEG O
. O

Targeted O
disruption O
of O
ATM O
leads O
to O
growth B
retardation I
, O
chromosomal B
fragmentation I
during I
meiosis I
, O
immune B
defects I
, O
and O
thymic B
lymphoma I
. O

Molecular O
bases O
of O
combined B
subtotal I
deficiencies I
of I
C6 I
and I
C7 I
: O
their O
effects O
in O
combination O
with O
other O
C6 B
and I
C7 I
deficiencies I
. O

The O
haplotype O
has O
been O
found O
in O
combination O
with O
a O
number O
of O
other O
haplotypes O
containing O
defective O
genes O
that O
lead O
either O
to O
C6 B
or I
C7 I
deficiency I
, O
but O
with O
different O
consequences O
. O

Our O
results O
indicate O
that O
the O
pathogenesis O
of O
C7D B
is O
heterogeneous O
like O
most O
of O
the O
other O
deficiencies B
of I
complement I
components I
. O
. O

HPRT B
- I
APRT I
- I
deficient I
mice O
are O
not O
a O
model O
for O
lesch B
- I
nyhan I
syndrome I
. O

Complete B
hypoxanthine I
- I
guanine I
phosphoribosyl I
- I
transferase I
( I
HPRT I
) I
deficiency I
in O
humans O
results O
in O
the O
Lesch B
- I
Nyhan I
syndrome I
which O
is O
characterized O
, O
among O
other O
features O
, O
by O
compulsive O
self O
- O
injurious O
behavior O
. O

HPRT B
- I
deficient I
mice O
generated O
using O
mouse O
embryonic O
stem O
cells O
exhibit O
none O
of O
the O
behavioral O
symptoms O
associated O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
. O

Thus O
, O
APRT B
- I
HPRT I
- I
deficient I
mice O
, O
which O
are O
devoid O
of O
any O
purine O
salvage O
pathways O
, O
show O
no O
novel O
phenotype O
and O
are O
not O
a O
model O
for O
the O
behavioral B
abnormalities I
associated O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
as O
previously O
suggested O

BACKGROUND O
Allelic O
loss O
of O
chromosome O
18q O
predicts O
a O
poor O
outcome O
in O
patients O
with O
stage B
II I
colorectal I
cancer I
. O

3 O
percent O
, O
whereas O
in O
patients O
with O
DCC B
- I
negative I
tumors I
, O
the O
survival O
rate O
was O
61 O
. O

In O
stage B
II I
colorectal I
carcinomas I
, O
the O
absence O
of O
DCC O
identifies O
a O
subgroup O
of O
patients O
with O
lesions O
that O
behave O
like O
stage B
III I
cancers I
. O

Association O
of O
anxiety B
- I
related I
traits I
with O
a O
polymorphism O
in O
the O
serotonin O
transporter O
gene O
regulatory O
region O
. O

Identification O
of O
WASP O
mutations O
, O
mutation O
hotspots O
and O
genotype O
- O
phenotype O
disparities O
in O
24 O
patients O
with O
the O
Wiskott B
- I
Aldrich I
syndrome I
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
, O
an O
X B
- I
linked I
immunodeficiency I
disease I
caused O
by O
mutation O
in O
the O
recently O
isolated O
gene O
encoding O
WAS B
protein O
( O
WASP O
) O
, O
is O
known O
to O
be O
associated O
with O
extensive O
clinical O
heterogeneity O
. O

Mutations O
at O
the O
5 O
end O
of O
APC B
are O
known O
to O
be O
associated O
with O
a O
relatively O
mild O
form O
of O
the O
disease O
, O
called O
attenuated B
adenomatous I
polyposis I
coli I
( O
AAPC B
) O
. O

Over O
100 O
distinct O
disease O
- O
associated O
mutations O
have O
been O
identified O
in O
the O
breast B
- I
ovarian I
cancer I
susceptibility O
gene O
BRCA1 O
. O

Here O
we O
report O
two O
families O
with O
HPT B
- I
JT I
syndrome I
in O
which O
adult B
renal I
hamartomas I
or O
cystic B
kidney I
disease I
were O
prominent O
associated O
features O
, O
possibly O
representing O
a O
new O
phenotypic O
variant O
of O
the O
HPT B
- I
JT I
syndrome I
. O

Here O
we O
report O
two O
families O
with O
HPT B
- I
JT I
syndrome I
in O
which O
adult B
renal I
hamartomas I
or O
cystic B
kidney I
disease I
were O
prominent O
associated O
features O
, O
possibly O
representing O
a O
new O
phenotypic O
variant O
of O
the O
HPT B
- I
JT I
syndrome I
. O

BRCA1 O
mutations O
cause O
increased O
risk O
for O
breast B
and I
ovarian I
cancer I
, O
frequently O
of O
early O
onset O
. O

These O
common O
mutations O
have O
an O
etiological O
role O
in O
many O
breast B
and I
ovarian I
cancer I
cases O
and O
provide O
the O
opportunity O
to O
examine O
genotype O
- O
phenotype O
correlations O
and O
genotype O
- O
environment O
interactions O
in O
individuals O
with O
the O
identical O
BRCA1 O
lesion O
. O

R841W O
is O
likely O
to O
be O
an O
etiologically O
significant O
lesion O
with O
involvement O
in O
close O
to O
1 O
% O
( O
95 O
% O
confidence O
interval O
of O
0 O
- O
1 O
. O
7 O
% O
) O
of O
all O
breast B
and I
ovarian I
cancers I
in O
this O
population O
. O

A O
further O
seven O
( O
13 O
% O
) O
of O
the O
patients O
reported O
breast B
/ I
ovarian I
cancer I
in O
at O
least O
one O
second O
- O
degree O
relative O
and O
in O
no O
first O
- O
degree O
relatives O
. O

The O
remaining O
eight O
cases O
( O
89 O
% O
) O
of O
male B
breast I
cancer I
with O
a O
family O
history O
of O
breast B
/ I
ovarian I
cancer I
in O
first O
- O
degree O
relatives O
remain O
unaccounted O
for O
by O
mutations O
in O
either O
the O
BRCA1 O
gene O
or O
the O
BRCA2 O
gene O
. O
. O

We O
conclude O
that O
the O
codon O
change O
N314D O
in O
cis O
with O
the O
base O
- O
pair O
transition O
1721C O
- O
- O
> O
T O
produces O
the O
LA B
variant I
of I
galactosemia I
and O
that O
this O
nucleotide O
change O
increases O
GALT O
activity O
by O
increasing O
GALT O
protein O
abundance O
without O
increasing O
transcription O
or O
decreasing O
thermal O
lability O
. O

Nonsense O
mutation O
in O
exon O
3 O
of O
the O
proteolipid O
protein O
gene O
( O
PLP O
) O
in O
a O
family O
with O
an O
unusual O
form O
of O
Pelizaeus B
- I
Merzbacher I
disease I
. O

We O
report O
a O
G O
- O
- O
> O
A O
transition O
at O
nucleotide O
431 O
of O
the O
proteolipid O
protein O
gene O
( O
PLP O
) O
results O
in O
a O
nonsense O
codon O
in O
a O
family O
with O
an O
unusual O
form O
of O
Pelizaeus B
- I
Merzbacher I
disease I
( O
PMD B
) O
. O

The O
nonsense O
mutation O
, O
which O
is O
in O
exon O
3B O
, O
should O
block O
the O
synthesis O
of O
normal O
PLP O
but O
spare O
DM20 O
, O
the O
isoform O
whose O
persistence O
has O
been O
associated O
with O
mild O
forms O
of O
PLP B
- I
associated I
disease I
in O
both O
humans O
and O
mice O
. O
. O

Common O
BRCA1 O
variants O
and O
susceptibility O
to O
breast B
and I
ovarian I
cancer I
in O
the O
general O
population O
. O

We O
have O
examined O
the O
frequency O
of O
four O
of O
these O
polymorphisms O
Gln356Arg O
, O
Pro871Leu O
, O
Glu1038Gly O
and O
Ser1613Gly O
in O
large O
series O
of O
breast B
and I
ovarian I
cancer I
cases O
and O
matched O
controls O
. O

Thus O
the O
most O
common O
polymorphisms O
of O
the O
BRCA1 O
gene O
do O
not O
make O
a O
significant O
contribution O
to O
breast B
or I
ovarian I
cancer I
risk O
. O

The O
Schwartz B
- I
Jampel I
syndrome I
( O
SJS B
; O
chondrodystrophic B
myotonia I
; O
McK O
255 O
, O
800 O
) O
is O
a O
recessively B
inherited I
condition I
defined O
by O
myotonia B
, O
short B
stature I
, O
and O
bone B
dysplasia I
. O

While O
only O
5 O
% O
of O
sporadic B
Wilms I
tumours I
have O
intragenic O
WT1 O
mutations O
, O
> O
90 O
% O
of O
patients O
with O
the O
Denys B
- I
Drash I
syndrome I
( O
renal B
nephropathy I
, O
gonadal B
anomaly I
, O
predisposition B
to I
WT I
) O
carry O
constitutional O
intragenic O
WT1 O
mutations O
. O

WT1 O
mutations O
have O
also O
been O
reported O
in O
juvenile B
granulosa I
cell I
tumour I
, O
non B
- I
asbestos I
related I
mesothelioma I
, O
desmoplastic B
small I
round I
cell I
tumour I
and O
, O
most O
recently O
, O
acute B
myeloid I
leukemia I
. O
. O

A O
mutation O
in O
autosomal B
dominant I
myotonia I
congenita I
affects O
pore O
properties O
of O
the O
muscle O
chloride O
channel O
. O

Autosomal B
dominant I
myotonia I
congenita I
is O
an O
inherited B
disorder I
of I
skeletal I
muscle I
caused O
by O
mutations O
in O
a O
voltage O
- O
gated O
Cl O
- O
channel O
gene O
( O
CLCN1 O
, O
7q35 O
) O
. O

The O
rates O
were O
higher O
among O
women O
from O
families O
with O
a O
history O
of O
both O
breast B
and I
ovarian I
cancer I
. O

Among O
family O
members O
, O
an O
average O
age O
of O
less O
than O
55 O
years O
at O
the O
diagnosis O
of O
breast B
cancer I
, O
the O
presence O
of O
ovarian B
cancer I
, O
the O
presence O
of O
breast B
and I
ovarian I
cancer I
in O
the O
same O
woman O
, O
and O
Ashkenazi O
Jewish O
ancestry O
were O
all O
associated O
with O
an O
increased O
risk O
of O
detecting O
a O
BRCA1 O
mutation O
. O

We O
hypothesize O
that O
the O
patient O
is O
heterozygous O
for O
a O
complete B
deficiency I
of I
C9 I
and O
for O
a O
gene O
directing O
hyposynthesis O
of O
a O
defective O
C9 O
. O

Screening O
for O
ESR O
mutations O
in O
breast B
and I
ovarian I
cancer I
patients O
. O

Molecular O
heterogeneity O
of O
classical B
and I
Duarte I
galactosemia I
: O
mutation O
analysis O
by O
denaturing O
gradient O
gel O
electrophoresis O
. O

To O
study O
the O
molecular O
genetics O
of O
classical B
and I
Duarte I
galactosemia I
, O
we O
analyzed O
the O
GALT O
mutations O
in O
30 O
families O
with O
classical B
galactosemia I
, O
in O
10 O
families O
with O
the O
D O
- O
2 O
variant O
and O
in O
3 O
individuals O
carrying O
the O
D O
- O
1 O
allele O
by O
denaturing O
gradient O
gel O
electrophoresis O
( O
DGGE O
) O
. O

Chromosomal O
translocations O
identified O
in O
hematopoietic B
and I
solid I
tumors I
result O
in O
deregulated O
expression O
of O
protooncogenes O
or O
creation O
of O
chimeric O
proteins O
with O
tumorigenic O
potential O
. O

Mutations O
in O
atm O
and O
p53 O
cause O
the O
human O
cancer B
- I
associated I
diseases I
ataxia B
- I
telangiectasia I
and O
Li B
- I
Fraumeni I
syndrome I
, O
respectively O
. O

Mutations O
in O
atm O
and O
p53 O
cause O
the O
human O
cancer B
- I
associated I
diseases I
ataxia B
- I
telangiectasia I
and O
Li B
- I
Fraumeni I
syndrome I
, O
respectively O
. O

Atm O
- O
null O
mice O
, O
as O
well O
as O
those O
null O
for O
p53 O
, O
develop O
mainly O
T B
- I
cell I
lymphomas I
, O
supporting O
the O
view O
that O
these O
genes O
have O
similar O
roles O
in O
thymocyte O
development O
. O

Myotonic B
dystrophy I
, O
or O
dystrophia B
myotonica I
( O
DM B
) O
, O
is O
an O
autosomal B
dominant I
multisystem I
disorder I
caused O
by O
the O
expansion O
of O
a O
CTG O
trinucleotide O
repeat O
in O
the O
3 O
untranslated O
region O
of O
the O
DMPK O
protein O
kinase O
gene O
on O
chromosome O
19q13 O
. O

